Navigation Links
Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
Date:7/13/2010

ASHBURN, Va., July 13 /PRNewswire/ -- Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies Ltd., has submitted a Special Protocol Assessment (SPA) for a proposed phase 3 clinical trial to support the U.S. approval of Cogenzia™:  Innocoll's topical antibiotic therapy for the adjuvant treatment of infected diabetic foot ulcers.

The protocol was developed following an End of Phase 2 meeting with FDA where the results of Innocoll's phase 2 clinical studies were presented and discussed. In the planned phase 3 randomized, placebo-controlled, double-blind clinical trial, patients with a moderate or severe diabetic foot infection will be treated with Cogenzia on a daily basis as an adjunct to standard-of-care, which includes systemic antibiotic therapy administered by the oral or intravenous route. Patients will be treated for a maximum of 28 days and the primary endpoint will be the percentage of patients who are clinically cured of infection 10 days after discontinuation of all antibiotic therapy. The study design is based on a highly encouraging phase 2 trial where 100% of Cogenzia-treated patients who completed the study achieved clinical cure, which was statistically significantly superior to 70% of patients in the control group (P = 0.024). Patients in the Cogenzia group also had a significantly higher rate of baseline pathogen eradication and a reduced time to pathogen eradication (P < 0.001).

Dr. Michael Myers, Innocoll's President and CEO commented, "Building on the strength of the phase II data, we continue to make great strides in the development of our lead product, Cogenzia.   We are particularly encouraged by the fact that the product will be developed as adjuvant therapy for use in conjunction with systemic
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
2. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
6. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
11. Advanced Life Sciences Submits Updated Special Protocol Assessment to FDA for Restanza in Community Acquired Bacterial Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Decision Resources Group finds that the market for ... billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin ... by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, ...
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, ... leader in noninvasive medical monitoring, today announced that the ... Model 3231 OEM/eHealth finger pulse oximeter for use in ... pulse oximeter plugs into a telemedicine hub or kiosk ... pulse rate in pediatric to adult patients. The Model ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... to Produce Therapeutic Proteins at Tumor,Site, ARLINGTON ... surgeons have delivered cancer fighting proteins through,skin flaps ... 79 percent reduction,in tumor volume, according to a ... Surgery(R), the official medical journal of the American,Society ...
... today announced the submission of a supplemental New ... Administration (FDA) for SEROQUEL XR(TM),(quetiapine fumarate) Extended-Release Tablets ... disorder (GAD), including maintenance of,antianxiety effect. It is ... an,atypical antipsychotic medicine in GAD. The submission is ...
Cached Medicine Technology:Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8
(Date:8/28/2014)... 2014 Valero Renewable Fuels Company, LLC, ... VLO), and the Ports of Indiana hosted Lt. Gov. ... at a Port Appreciation and Welcome Celebration commemorating the ... , “The opening of Valero’s ethanol facility at the ... development win for the State of Indiana,” Ellspermann said. ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. ... electrical currents through the scalp to a specific network of ... day. In a small study of healthy young adults, ... networks involved in memory. That, in turn, boosted participants, performance ... the brain stimulation. During TMS, an electromagnetic coil is ...
(Date:8/28/2014)... IL (PRWEB) August 28, 2014 Data ... Supplement shows that while most hospitals utilize a basic ... health care information technology is still a challenge. ... the August issue of Health Affairs , and ... Forum’s Health Care Data Center, as well as Chantal ...
(Date:8/28/2014)... is hurting reproduction of the endangered Devils Hole pupfish, threatening ... few as 35 individuals, new research by the University of ... that geothermal water on a small shelf near the surface ... pupfish live is heating up as a result of climate ... , The hotter water, which now reaches more than ...
(Date:8/28/2014)... 28, 2014 Dr. Paul Kovatis is being ... the U.S. military for his efforts to treat many wounded ... Warriors Foundation and several other military organizations. Dr. Kovatis’ ... in WWII. Having five members of his immediate family ... Cemetery, it’s no wonder Dr. Kovatis is so dedicated to ...
Breaking Medicine News(10 mins):Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 2Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis 2
... survey reveals that 61% of Australians are not aware of the ... the Salvation Army survey, binge drinking was "worryingly high" among teenage ... 41 % of the18 to 24-year-olds confessed to take not less ... ,"What is of such concern is that people don't know ...
... New York: An investigation into the degree of consequence type ... the condition before 50 years//, led to the finding that ... say Swedish researchers. ,The status of type ... measured with the presence of biological identification in the blood ...
... well known that the output of nerve cells is the ... is still unclear about how widely separated regions of the ... complex activity. A new study by neuroscientists at the University ... Francisco (UCSF) is getting to resolve this mystery. ...
... the degree of hangover one might experience, after a night ... delved into this arena, and studied the connection between the ... by being hangover less as compared to the ones with ... a hangover, characterized by an unbearable headache, nausea, dry mouth ...
... type 1 Diabetes was admitted to the Clinical Research Center ... // Four days later the North Shore suburban girl was ... body and ready to spend a few days at the ... to do well, her insulin was reduced day by day. ...
... would benefit a lot if they were given albumin ... in London and experts in Kenya have developed this ... with malaria. ,In initial studies less ... new treatment died, researchers said. "The observation is that ...
Cached Medicine News:Health News:The need for cancer warnings on alcohol packaging 2Health News:Slow brain waves integral in coordination of complex activity 2Health News:Molecular Medicine And Diabetes 2Health News:Molecular Medicine And Diabetes 3Health News:Molecular Medicine And Diabetes 4Health News:Molecular Medicine And Diabetes 5Health News:Molecular Medicine And Diabetes 6Health News:Molecular Medicine And Diabetes 7
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: